RxDoctor Payments Data

Hafiz Imran, MD

Interventional Cardiology · Providence, RINPI 1962705590

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (58.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Medtronic at 34.4% of the total. Reporting peaked in 2023 at $10,786 and has fallen 75.7% since, to $2,626 in 2025.

$17,985in general payments, 2019–2025

Across 131 payments — averaging $137.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Abbott$5K
  • Edwards Lifesciences$4K
  • Boston Scientific$372
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$266
  • Novartis$214
  • plus $2K from 24 others

What the payments were for

  • Grants$10,50058%
  • Travel & lodging$2,98717%
  • Food & beverage$4,33124%
  • Education$1671%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,985 in reported general payments places this provider in the 70th percentile of 23 interventional cardiology providers in Rhode Island.

See all interventional cardiology providers in Rhode Island

Medicare billing

Part B allowed, 2024
$125,353
Medicare patients
454
Services billed
829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin20$15,647
EliquisApixaban14$12,924
Rosuvastatin Calcium14$573
Metoprolol Succinate31$506
Atorvastatin Calcium32$459
Carvedilol16$237
ClopidogrelClopidogrel Bisulfate14$229
Losartan Potassium19$171
Spironolactone16$111
Amlodipine Besylate12$69
Furosemide19$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$138$15,64720 claims
PfizerEliquis$168$12,92414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 23 interventional cardiology providers in Rhode Island.

Other interventional cardiology in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →